FDA is encouraging supplemental NDAs for TRT to treat low libido in idiopathic hypogonadism, reflecting preliminary ...

High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance ...

The July 2026 advisory review could reopen compounding pathways for peptides previously curtailed in 2023 over immunogenicity ...

Metabolic disease is reshaping care delivery and costs, with experts at the Academy of Managed Care Pharmacy (AMCP) 2026 ...

At AMCP 2026, Daryl Pritchard, PhD, highlighted fragmentation, evidence gaps, and decision support needs limiting precision ...

The end of 2025 saw the expiration of the enhanced premium subsidies under the Affordable Care Act (ACA) after Congress was ...

Kelsea Aragon, PharmD, highlights the role of long-acting HIV therapies like lenacapavir and cabotegravir in improving ...

The authors updated a diagnosis list to identify low-acuity emergency department visits by veterans and applied it to examine ...

In addition to the models, Taddei-Allen also pointed out the overall shift in employer plan drug costs, shifting more of the ...

Results released April 1, 2026, by the American Society for Radiation Oncology (ASTRO), which represents more than 10,000 ...

Managed care organizations must move beyond early, low-risk artificial intelligence (AI) use to strategically governed, ...

Adam Colburn, JD, highlights 3 federal bills to expand value-based care, digital therapeutics, and pharmacist reimbursement ...